91 results about "CD36" patented technology

There is provided a method of inhibiting the occurrence of one of more of the following conditions:—the proliferation of monocytes / macrophages; or—the proliferation of smooth muscle cells; or—the expression of CD36 receptors; or—the uptake of oxidized LDL, the method comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents.

The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.

The invention provides an establishing method of a CD36 mutant gene stable eukaryotic expression cell line causing CD36 deletion. The method comprises a while process of extracting total RNA from a CD36 deletion individual and conducting reverse transcription so as to obtain CD36 cDNA of whole segment of a CD36 mutant gene open reading frame; establishing a recombinant cloning vector containing the CD36 mutant gene cDNA and an EGFP fluorescent reporter gene, transforming the recombinant cloning vector into escherichia coli, and conducting plasmid amplification and identification; and transfecting the recombinant cloning vector into CHO-K1 cells, and conducting screening and identification so as to obtain the CD36 mutant gene stable eukaryotic expression cell line. The CD36 is distributed in a plurality of cells and tissues, and CD36 encoding gene mutation can cause the CD36 deletion in the individual. The CD36 takes an important effect in various physiological and pathological processes, involving such diseases as platelet homologous immunization, hypercholesteremia, diabetes, malaria and the like. With the application, the CD36 mutant gene stable eukaryotic expression cell line, which is established by virtue of the technology, can provide a resource and a working platform for researching the structure and the functions of the CD36, explaining physiological and pathological mechanisms which the CD36 participate in and discussing a role in clinical treatment and drug research and development.

This invention relates to antibodies that specific bind to fetal CD36+ cells in preference to binding to maternal CD36+ cells and methods for using these antibodies to detect and separate fetal cells from adult biological fluids including maternal peripheral blood.

Provided herein is approach that specifically modulates the activity and / or the number of intratumoral regulatory T (Treg) cells in a subject. Such an approach can be used to reduce the number of intratumoral T regulatory cells in a subject as well as to inhibit tumor growth in a subject having a cancer without eliciting autoimmune responses. The approach relies on the inhibition of CD36 or of PPARbeta.

According to the invention there is provided a method of treatment or prophylaxis of atherosclerosis, hypercholesterolemia or a cardiovascular disease associated with atherosclerosis, which method comprises administration of one or more Growth Hormone Releasing Peptides (GHRPs) to a patient in need of such treatment or prophylaxis. There are also provided methods of reducing blood plasma cholesterol levels, as well as methods of modulating the expression of the scavenger receptor CD36 and genes involved in cellular cholesterol efflux.